发布求助
文献互助 智能选刊 最新文献

Lung Cancer Management最新文献

筛选
英文 中文
Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study 阿法替尼治疗化疗后携带常见EGFR突变的局部晚期/转移性NSCLC：一项IV期研究
IF 2.8
Lung Cancer Management Pub Date : 2019-09-02 DOI: 10.2217/lmt-2019-0004
S. Thongprasert, Sarayut Lucien Geater, D. Clement, A. Abdelaziz, J. Reyes-Igama, D. Jovanovic, A. Alexandru, M. Schenker, V. Sriuranpong, P. Serwatowski, S. Suresh, A. Cseh, R. Gaafar
{"title":"Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study","authors":"S. Thongprasert, Sarayut Lucien Geater, D. Clement, A. Abdelaziz, J. Reyes-Igama, D. Jovanovic, A. Alexandru, M. Schenker, V. Sriuranpong, P. Serwatowski, S. Suresh, A. Cseh, R. Gaafar","doi":"10.2217/lmt-2019-0004","DOIUrl":"https://doi.org/10.2217/lmt-2019-0004","url":null,"abstract":"Aim: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) following chemotherapy. Patients & methods: In this open-label, single-arm Phase IV study, patients with EGFRm+ (Del19/L858R) NSCLC who had progressed following platinum-based chemotherapy received afatinib (starting dose 40 mg/day). The primary end point was confirmed objective response. Results: 60 patients received afatinib for a median duration of 11.5 months. 50% of patients had a confirmed objective response, of median duration 13.8 months. Median progression-free survival was 10.9 months. The most common treatment-related adverse events were diarrhea (72%), rash (28%) and paronychia (23%). Conclusion: Our data support the use of afatinib (40 mg/day) as an effective and well-tolerated second-line treatment in EGFRm+ NSCLC.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2019-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48795205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity? 神经内分泌阴性的小细胞肺癌和WT RB1型的大细胞神经内分泌癌是同一实体的两面吗?
IF 2.8
Lung Cancer Management Pub Date : 2019-08-21 DOI: 10.2217/lmt-2019-0005
D. Sonkin, Anish Thomas, B. Teicher
{"title":"Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?","authors":"D. Sonkin, Anish Thomas, B. Teicher","doi":"10.2217/lmt-2019-0005","DOIUrl":"https://doi.org/10.2217/lmt-2019-0005","url":null,"abstract":"Until recently, small cell lung cancer (SCLC) was described as SCLC and SCLC variant, based upon cellular morphology and loss of neuroendocrine markers in the SCLC variant. However, based on recent research advances, driven in part by the increase in comprehensive genomic data, it has become clear that there are multiple SCLC subtypes including an ASCL1 and NEUROD1 low, YAP1 high (SCLC-Y) subtype enriched for WT RB1. Comparing morphological and other features of this SCLC subtype to neuroendocrine negative RB1, KEAP1, STK11 WT LCNEC raises a number of important questions with diagnostic and therapeutic implications.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2019-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44348774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
Stereotactic body radiation therapy versus fractionated radiation therapy for early-stage bronchopulmonary carcinoid 立体定向放射治疗与分级放射治疗早期支气管肺类癌的比较
IF 2.8
Lung Cancer Management Pub Date : 2019-08-21 DOI: 10.2217/lmt-2019-0003
R. Wegner, S. Abel, Z. Horne, S. Hasan, A. Colonias, V. Verma
{"title":"Stereotactic body radiation therapy versus fractionated radiation therapy for early-stage bronchopulmonary carcinoid","authors":"R. Wegner, S. Abel, Z. Horne, S. Hasan, A. Colonias, V. Verma","doi":"10.2217/lmt-2019-0003","DOIUrl":"https://doi.org/10.2217/lmt-2019-0003","url":null,"abstract":"Aim: To compare trends and outcomes in early stage bronchopulmonary carcinoid (BPC) tumors treated nonoperatively with conventionally fractionated radiotherapy (CFRT) and stereotactic body radiotherapy (SBRT). Methods/materials: We queried the National Cancer Database for primary (typical) BPC staged cT1-2N0M0 and treated nonsurgically with lung-directed radiation and ≥1 month of follow-up. Odds ratios were used to predict likelihood of SBRT treatment and multivariable Cox regression determined predictors of survival. Results: Out of 154 patients, 84 (55%) were treated with SBRT and the remainder were treated with CFRT. Although SBRT use was 0% from 2004 to 2007, it varied from 50 to 70% per year thereafter. Propensity-matched Kaplan–Meier analysis revealed improved survival with lung SBRT (median: 66 vs 58 months; p = 0.034). Conclusion: SBRT for early stage, primary BPC has increased over time and was associated with higher survival than CFRT.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2019-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42304463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer 免疫检查点抑制剂治疗癌症挽救性化疗的疗效和安全性
IF 2.8
Lung Cancer Management Pub Date : 2019-05-09 DOI: 10.2217/lmt-2019-0001
M. Tone, T. Izumo, Nobuyasu Awano, N. Kuse, M. Inomata, Tatsunori Jo, Hanako Yoshimura, S. Miyamoto, H. Kunitoh
{"title":"Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer","authors":"M. Tone, T. Izumo, Nobuyasu Awano, N. Kuse, M. Inomata, Tatsunori Jo, Hanako Yoshimura, S. Miyamoto, H. Kunitoh","doi":"10.2217/lmt-2019-0001","DOIUrl":"https://doi.org/10.2217/lmt-2019-0001","url":null,"abstract":"Aim: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. Patients & methods: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. Results: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. Conclusion: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"4 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2019-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44154321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report 一例转移性非小细胞肺癌癌症患者Pembrolizumab诱导的坏死性肌炎：病例报告
IF 2.8
Lung Cancer Management Pub Date : 2019-05-08 DOI: 10.2217/lmt-2018-0017
Jonas Claus, Annelies Van Den Bergh, Sanne Verbeek, E. Wauters, K. Nackaerts
{"title":"Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report","authors":"Jonas Claus, Annelies Van Den Bergh, Sanne Verbeek, E. Wauters, K. Nackaerts","doi":"10.2217/lmt-2018-0017","DOIUrl":"https://doi.org/10.2217/lmt-2018-0017","url":null,"abstract":"A 57-year-old man presented with swelling and pain in the lower limbs, inability to walk and increasing dyspnea for 2 days. Because of refractory stage IV non-small-cell lung cancer, pembrolizumab was started 21 days before presentation. Since then, he experienced general discomfort, fatigue and bilateral weakness in the legs with exercise limitation. A diagnosis of pembrolizumab-induced grade III myositis was made based on muscle biopsy. Pembrolizumab is a humanized monoclonal antibody against PD-1. It has been approved for the treatment of metastatic melanoma and refractory non-small-cell lung cancer with increased expression of PD-L1 on the cell surface of tumor cells. With such a humanized monoclonal antibody, fewer adverse events are expected than with systemic chemotherapy. However, 13% of patients develop autoimmune side effects which can be severe (grade III, IV or V) in 5–10%. We discuss a case of pembrolizumab-induced myositis, with a brief overview of the literature. Only three cases of pembrolizumab-induced myositis have been reported in literature.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2019-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2018-0017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47627281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors 同时接受二甲双胍和免疫检查点抑制剂治疗的非小细胞肺癌患者的临床结果
IF 2.8
Lung Cancer Management Pub Date : 2019-05-07 DOI: 10.2217/lmt-2018-0016
M. Afzal, K. Dragnev, Tayyaba Sarwar, K. Shirai
{"title":"Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors","authors":"M. Afzal, K. Dragnev, Tayyaba Sarwar, K. Shirai","doi":"10.2217/lmt-2018-0016","DOIUrl":"https://doi.org/10.2217/lmt-2018-0016","url":null,"abstract":"Aim: To study the clinical benefits of concurrent metformin and immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer patients. Materials & methods: This is a retrospective review of 50 non-small-cell lung cancer patients receiving ICIs with metformin (cohort A) or without metformin (cohort B). Patients were also stratified by ICIs as second-/third-line therapy. Results: Overall response rate and disease control rate were higher in cohort A (41.1 vs 30.7%, p = 0.4 and 70.5 vs 61.6%, p = 0.5, respectively). Median overall survival and progression-free survival were also higher in cohort A (11.5 vs 7.6 months, p = 0.5 and 4.0 vs 3.0 months, p = 0.6, respectively). On subset analysis (second-/third-line ICIs), overall response rate, disease control rate, median overall survival, progression-free survival were also higher in cohort A. Conclusion: Despite the small-sample size, we observed improved clinical outcomes in patients who received ICIs in combination with metformin.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2019-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2018-0016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47909585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 52
Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications. 早期NSCLC的立体定向身体放射治疗：历史回顾、当代证据和未来意义。
IF 0.9
Lung Cancer Management Pub Date : 2019-02-27 eCollection Date: 2019-02-01 DOI: 10.2217/lmt-2018-0013
Stephen Abel, Shaakir Hasan, Zachary D Horne, Athanasios Colonias, Rodney E Wegner
{"title":"Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications.","authors":"Stephen Abel, Shaakir Hasan, Zachary D Horne, Athanasios Colonias, Rodney E Wegner","doi":"10.2217/lmt-2018-0013","DOIUrl":"10.2217/lmt-2018-0013","url":null,"abstract":"<p><p>Clinical use of stereotactic body radiation therapy (SBRT) has increased dramatically over the last 2 decades and is the current standard-of-care in cases of inoperable early stage non-small-cell lung cancer. While surgical resection remains the standard-of-care for operable patients, several ongoing clinical trials are investigating the role of SBRT in these operative candidates as well. Taking into consideration the expanding role and utility of SBRT, this paper will: review the historical basis of SBRT; examine landmark trials establishing the framework for the current body of evidence; discuss areas of active and future research; and identify epidemiological trends that are likely to further increase the use of SBRT.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"8 1","pages":"LMT09"},"PeriodicalIF":0.9,"publicationDate":"2019-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/5d/lmt-08-09.PMC6488937.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37202752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting claudin-3 suppresses stem cell-like phenotype in nonsquamous non-small-cell lung carcinoma. 靶向克劳丁-3可抑制非鳞状非小细胞肺癌的干细胞样表型。
IF 0.9
Lung Cancer Management Pub Date : 2019-02-26 eCollection Date: 2019-02-01 DOI: 10.2217/lmt-2018-0010
Lin Ma, Wu Yin, Heliang Ma, Ihab Elshoura, Lan Wang
{"title":"Targeting claudin-3 suppresses stem cell-like phenotype in nonsquamous non-small-cell lung carcinoma.","authors":"Lin Ma, Wu Yin, Heliang Ma, Ihab Elshoura, Lan Wang","doi":"10.2217/lmt-2018-0010","DOIUrl":"10.2217/lmt-2018-0010","url":null,"abstract":"<p><strong>Aim: </strong>To determine the role of claudin-3 in cancer stemness in nonsquamous non-small-cell lung carcinoma (NSCLC).</p><p><strong>Materials & methods: </strong><i>In vitro/vivo</i> extreme limiting dilution analysis and the side population assay were used to investigate the role of claudin-3 in regulating cancer stemness in nonsquamous NSCLC.</p><p><strong>Results & conclusion: </strong>Claudin-3 depletion decreased the formation rates of spheres and tumors and increased cisplatin sensitivity. Claudin-3 was also identified as one downstream target of estrogen receptor-α in regulating cancer stemness. Moreover, targeting <i>CLDN-3</i> transcription by small molecules including withaferin A, estradiol and fulvestrant suppressed cancer stemness and reversed chemoresistance. These results demonstrated claudin-3 is one positive regulator of cancer stemness in nonsuqamous NSCLC.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"8 1","pages":"LMT04"},"PeriodicalIF":0.9,"publicationDate":"2019-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f6/d0/lmt-08-04.PMC6488947.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37202749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
We need to educate young lung cancer patients about menopause risk. 我们需要对年轻肺癌患者进行更年期风险教育。
IF 0.9
Lung Cancer Management Pub Date : 2019-02-12 eCollection Date: 2019-02-01 DOI: 10.2217/lmt-2018-0018
Fahad Faruqi, Elizabeth Cathcart-Rake, Kathryn J Ruddy
{"title":"We need to educate young lung cancer patients about menopause risk.","authors":"Fahad Faruqi, Elizabeth Cathcart-Rake, Kathryn J Ruddy","doi":"10.2217/lmt-2018-0018","DOIUrl":"10.2217/lmt-2018-0018","url":null,"abstract":"","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"8 1","pages":"LMT08"},"PeriodicalIF":0.9,"publicationDate":"2019-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5e/b9/lmt-08-08.PMC6488940.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37202751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung stereotactic body radiotherapy after past ablative therapy: a single institution case series. 既往消融治疗后肺立体定向放射治疗:单一机构病例系列。
IF 2.8
Lung Cancer Management Pub Date : 2018-12-21 eCollection Date: 2018-11-01 DOI: 10.2217/lmt-2018-0012
Rodney E Wegner, Nissar Ahmed, Shaakir Hasan, Lana Y Schumacher, Athanasios Colonias
{"title":"Lung stereotactic body radiotherapy after past ablative therapy: a single institution case series.","authors":"Rodney E Wegner,&nbsp;Nissar Ahmed,&nbsp;Shaakir Hasan,&nbsp;Lana Y Schumacher,&nbsp;Athanasios Colonias","doi":"10.2217/lmt-2018-0012","DOIUrl":"https://doi.org/10.2217/lmt-2018-0012","url":null,"abstract":"<p><strong>Aim: </strong>Non-small-cell lung cancer recurs locally 10-40% of the time after local therapy, presenting a therapeutic challenge given poor pulmonary reserve. Herein, we seek to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) for retreatment of such patients.</p><p><strong>Methods: </strong>We identified and reviewed clinical outcomes in ten patients with recurrent non-small-cell lung cancer after past vicryl mesh brachytherapy.</p><p><strong>Results: </strong>Ten patients with a median age of 77 were treated to a median dose of 48 Gy in five fractions. Local control at 1 year was 88%. There was one distant failure at 29 months. There was no significant toxicity after SBRT.</p><p><strong>Conclusion: </strong>SBRT is safe and effective when used for re-irradiation after past ablative therapies.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"7 3","pages":"LMT05"},"PeriodicalIF":2.8,"publicationDate":"2018-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2018-0012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36925403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信